Document is current
Any future updates will be listed below
-
Authors
Millard, Thomas https://orcid.org/0000-0002-4516-8929
Sammour, Fatin https://orcid.org/0000-0001-7134-6963
Anthias, Chloe
Easdale, Sandra
Gonzalez-Arias, Carlos
Ethell, Mark
Potter, Mike
Iyengar, Sunil
El-Sharkawi, Dima
Attygalle, Ayoma D.
Chau, Ian https://orcid.org/0000-0003-0286-8703
Cunningham, David https://orcid.org/0000-0001-5158-1069
Nicholson, Emma
Sharma, Bhupinder https://orcid.org/0000-0002-5922-9630
- License Information
-
More Information
Article History
Received: 24 June 2021
Revised: 15 September 2021
Accepted: 24 September 2021
First Online: 5 October 2021
Competing interests
: EN: KITE/Gilead—advisory board, conference fees support, speaker fees. Novartis—advisory board, conference fees support. BMS/Celgene—Ad Board. Pfizer—Ad board. DE-S: Honoraria—Abbvie, AstraZeneca, Janssen, Roche and Takeda. Conference/Travel support—Abbvie and Novartis. Ad boards: Abbvie, ASTEX, AstraZeneca, Beigene, Janssen and Kyowa Kiirin. IC: Advisory Board—Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics, Astra-Zeneca, OncXerna, Pierre Fabre, Boehringer Ingelheim and Incyte. Research funding: Eli-Lilly, Janssen-Cilag and Sanofi Oncology. Honorarium: Eli-Lilly. DC: MedImmune /AZ, Clovis, Eli-Lilly, 4SC, Bayr, Celgene, NIHR EME, Leap and Roche, and participated on the advisory board for OVIBIO.
